Veradermics, Incorporated (NYSE: MANE)
Health Care · Pharmaceuticals · US
$125.45
-4.17% today · +246.8% 1Y
Veradermics, Incorporated (NYSE: MANE) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $5.47B and employs 37 people.
Over the last twelve months the share price has gained 246.8%, trading between 32.00 and 136.72.
Tweenvest scores Veradermics, Incorporated across four factors: quality 45/100, value 71/100. Its strongest factor is value.
MANE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.47B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -6.44
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $136.72
- 52-week low
- $32.00
- Avg volume (3M)
- —
- Shares outstanding
- 41.78M
- Employees
- 37
- Next earnings
- —
About Veradermics, Incorporated
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
- ISIN
- US9229671048
- Founded
- 2019
- Listed since
- Feb 4, 2026
- Exchange
- New York Stock Exchange
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.SZSE: 000999 | $6.17B | CN¥24.82 | +1.39% |
| Ligand Pharmaceuticals IncorporatedNasdaqGM: LGND | $6.02B | $305.19 | +1.12% |
| Abbott India LimitedBSE: 500488 | $5.71B | Rs25,999.85 | -3.10% |
| Shanghai Allist Pharmaceuticals Co., Ltd.SHSE: 688578 | $5.54B | CN¥82.50 | -26.06% |
| Gland Pharma LimitedNSEI: GLAND | $5.22B | Rs3,061.80 | +6.52% |
| Shenzhen Salubris Pharmaceuticals Co., Ltd.SZSE: 002294 | $5.12B | CN¥30.93 | +0.88% |
| Ipca Laboratories LimitedNSEI: IPCALAB | $5.02B | Rs1,915.40 | -1.43% |
| Beijing Tongrentang Co., LtdSHSE: 600085 | $4.97B | CN¥24.28 | +2.27% |
Figures last refreshed Oct 11, 2026.